cáncer

Seguir

Researchers have discovered that administering immunotherapy drugs for lung cancer in the morning can significantly improve patient survival rates. This approach leverages the body's circadian rhythms, which influence immune cell activity. The findings suggest a simple timing adjustment could enhance treatment effectiveness without added costs.

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar